Belpointe Asset Management Boosts Johnson & Johnson Holdings

Institutional investor increases stake in pharmaceutical giant by 30% in Q3 2025

Jan. 29, 2026 at 3:31am

Got story updates? Submit your updates here. ›

Belpointe Asset Management LLC, an institutional investor, grew its holdings in shares of Johnson & Johnson (NYSE: JNJ) by 30% during the third quarter of 2025, according to a recent SEC filing. The firm now owns 19,773 shares of the pharmaceutical company's stock, worth approximately $3.66 million.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a strong presence in pharmaceuticals, medical devices, and consumer products. Institutional investor activity in the stock can provide insights into market sentiment and future performance expectations.

The details

Belpointe Asset Management LLC increased its position in Johnson & Johnson by purchasing an additional 4,566 shares during the third quarter. The firm now holds a total of 19,773 shares of the company's stock, representing a 30% increase in its holdings compared to the previous quarter.

  • Belpointe Asset Management LLC filed the SEC report on January 29, 2026.
  • The reported increase in holdings occurred during the third quarter of 2025.

The players

Belpointe Asset Management LLC

An institutional investment firm that manages a portfolio of assets, including shares of Johnson & Johnson.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

The increase in Belpointe Asset Management's holdings in Johnson & Johnson suggests the firm sees potential for the stock to continue performing well. As a major player in the healthcare industry, Johnson & Johnson's financial performance and market position are closely watched by institutional investors.